Arrowhead Pharmaceuticals
ARWR
Arrowhead Pharmaceuticals (ARWR) earnings history
Most recent quarter
- Fiscal period
- Q3 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.36
- EPS estimate
- −$1.28
- EPS surprise
- −6.52%
- Revenue surprise
- +70.36%
- Revenue
- $75.3M
- Revenue estimate
- $44.2M
- Reported
- Aug 4, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | Aug 4, 2026 | −$1.28 | −$1.36 | −6.52% | $75.3M | SEC |
| Q2 2026 | May 7, 2026 | −$1.10 | −$0.93 | +15.07% | $73.7M | SEC |
| Q1 2026 | Feb 5, 2026 | $0.04 | $0.22 | +491.40% | $264.0M | SEC |
| Q4 2025 | Nov 25, 2025 | −$0.11 | −$0.11 | +1.43% | $256.5M | SEC |
| Q3 2025 | Aug 7, 2025 | −$0.95 | −$1.26 | −32.31% | $27.8M | SEC |
| Q2 2025 | May 12, 2025 | −$0.19 | $2.75 | +1567.45% | $542.7M | SEC |
| Q1 2025 | Feb 10, 2025 | −$0.48 | −$1.39 | −192.08% | $2.5M | SEC |
| Q4 2024 | Nov 26, 2024 | −$1.12 | −$1.36 | −21.39% | $0.00 | SEC |
| Q3 2024 | Aug 8, 2024 | −$0.53 | −$1.38 | −160.92% | $0.00 | SEC |
| Q2 2024 | May 9, 2024 | −$0.47 | −$1.02 | −116.15% | $0.00 | SEC |
| Q1 2024 | Feb 6, 2024 | −$0.80 | −$1.24 | −54.81% | $3.6M | SEC |
| Q4 2023 | Nov 29, 2023 | −$0.61 | −$1.02 | −67.60% | $16.1M | SEC |
| Q3 2023 | Aug 7, 2023 | −$0.57 | −$0.96 | −68.63% | $15.8M | SEC |
| Q2 2023 | May 2, 2023 | −$0.62 | $0.45 | +172.82% | $146.3M | SEC |
| Q1 2023 | Feb 6, 2023 | $0.37 | −$0.39 | −205.43% | $62.5M | SEC |
| Q4 2022 | Nov 28, 2022 | −$0.58 | −$0.80 | −36.99% | $31.6M | SEC |
| Q3 2022 | Aug 4, 2022 | −$0.57 | −$0.68 | −19.59% | $32.4M | SEC |
| Q2 2022 | May 10, 2022 | $0.14 | $0.41 | +182.95% | $151.8M | SEC |
| Q1 2022 | Feb 2, 2022 | −$0.45 | −$0.60 | −34.26% | $27.4M | SEC |
| Q4 2021 | Nov 22, 2021 | $0.05 | −$0.61 | −1376.15% | $38.3M | SEC |
Quarterly revenue
Frequently asked questions
When did Arrowhead Pharmaceuticals (ARWR) last report earnings?
Arrowhead Pharmaceuticals last reported on Aug 4, 2026, covering fiscal Q3 2026.
Did ARWR beat earnings estimates?
No. Arrowhead Pharmaceuticals reported EPS of −$1.36 for Q3 2026 against a −$1.28 estimate — a 6.52% miss.
How much revenue did ARWR report last quarter?
Arrowhead Pharmaceuticals reported $75.3M in revenue for Q3 2026, against a consensus estimate of $44.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.